Eli Lilly
FDA Approves FoundationOne CDx for Eli Lilly's Retevmo
The tissue-based test can determine if Retevmo is an appropriate treatment for patients with RET gene fusions.
Biocartis, Eli Lilly Partner for Spanish NSCLC Biomarker Study
The study aims to establish how Biocartis' Idylla molecular testing platform can eventually be used to improve community-based diagnostic workflows in the US.
Amoy Diagnostics PLC Panel Gets Approval in Japan as CDx for Retevmo in Non-Small Cell Lung Cancer
Oncologists in Japan can now use the AmoyDx Pan Lung Cancer PCR Panel to identify patients with RET fusions that make them eligible for treatment with the Eli Lilly drug.
OncoDNA, Eli Lilly Partner on Thyroid Cancer Biomarker Testing
The companies are working together to offer next-generation sequencing-based molecular testing on thyroid cancer biopsies to clinicians in Italy.
Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers
The NGS-based Oncomine Dx Target Test will help ID patients with advanced RET-driven lung and thyroid cancers who may be eligible for treatment with Eli Lilly's Retevmo.